EUCTR2010-019102-17-FR进行中（未招募）1 期
A PHASE III, PROSPECTIVE, MULTICENTRE, OPEN LABEL, EXTENSION STUDY ASSESSING THE LONG TERM SAFETY AND EFFICACY OF REPEATED TREATMENT WITH DYSPORT USED IN THE TREATMENT OF LOWER LIMB SPASTICITY IN CHILDREN WITH DYNAMIC EQUINUS FOOT DEFORMITY DUE TO CEREBRAL PALSY
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 221
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •All subjects must fulfil the following inclusion criteria to be eligible for the study:
- •(1) Completion of the double blind study (Study 141) up to the Week 12, Week 16, Week 22 or Week 28 follow up visit.
- •(2) Without any major protocol deviations and/or any ongoing AEs, either of which, in the opinion of the Investigator would pose an unacceptable risk to the subject were he/she to continue receiving treatment in this open label extension study.
- •(3) Written informed consent obtained from the child’s parent(s)/guardian(s) for this study, and assent from the child, when and where applicable.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Subjects are to be excluded if any of the following apply:
- •(1) Fixed myocontracture as defined by a passive range of motion (Xv1) of 10° or less in ankle dorsiflexion.
- •(2) Unwillingness or inability to comply with the protocol.
- •(3) Current need for surgery of the muscles of any affected limb.
- •(4) Treatment with any drug that interferes either directly or indirectly with neuromuscular function (e.g. aminoglycoside antibiotics or neuroblocking agents used during surgery e.g. curare) within the last 30 days prior to study medication or a planned treatment with such drugs.
- •(5) Be pregnant and/or lactating.
- •(6) Not willing to use contraceptive measures throughout the course of the study if post pubertal and sexually active.
- •(7) An infection at the injection site(s).
- •(8) Planned treatment with any new investigational drug or device during the
- •study period.
研究者
相似试验
进行中（未招募）
不适用
A PHASE III, PROSPECTIVE, MULTICENTRE, OPEN LABEL, EXTENSION STUDY ASSESSING THE LONG TERM SAFETY AND EFFICACY OF REPEATED TREATMENT WITH DYSPORT USED IN THE TREATMENT OF LOWER LIMB SPASTICITY IN CHILDREN WITH DYNAMIC EQUINUS FOOT DEFORMITY DUE TO CEREBRAL PALSYEUCTR2010-019102-17-PLIpsen Pharma SAS221
进行中（未招募）
3 期
A Phase 3 Study of ALXN2060 in Participants with Symptomatic Transthyretin Amyloid Cardiomyopathy (ATTR-CM).Transthyretin Amyloid Cardiomyopathy (ATTR-CM)ATTR-CMJPRN-jRCT2071200059Ishioka Tatsunari22
进行中（未招募）
1 期
A comparative study of MPDL3280A versus chemotherapy in patients with advanced bladder cancer.EUCTR2014-003231-19-GBF. Hoffmann-La Roche Ltd931
进行中（未招募）
1 期
A Phase III, Open-Label, Extension, Multicentre, Safety Study of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents Aged 6-17 with Attention-Deficit/Hyperactivity Disorder (ADHD)EUCTR2008-000720-10-FRShire Pharmaceutical Development Limited276
进行中（未招募）
1 期
A Phase III, Open-Label, Extension, Multicentre, Safety Study of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents Aged 6-17 with Attention-Deficit/Hyperactivity Disorder (ADHD)Attention Deficit / Hyperactivity Disorder (ADHD)MedDRA version: 9.1Level: LLTClassification code 10064104Term: ADHDEUCTR2008-000720-10-NLShire Pharmaceutical Development Limited232